

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	D. STENKAMP, et al	Art Unit:	1624
U.S. Appln. No.	10/647,156	Examiner:	T. TRUONG
U.S. Filing Date:	August 22, 2003	Confirmation No:	1272
Title of Invention:	New Carboxamide Compounds having Melanin Concentrating Hormone Antagonistic Activity, Pharmaceutical Preparations Comprising these Compounds and Process for their Manufacture		
Attorney Docket No.:	01-1387		

Filed Electronically Via EFS-Web  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REPLY TO NON-FINAL OFFICE ACTION**

Sir:

This Reply is being filed in response to the September 11, 2008 non-final Office Action issued in the above-identified application. Applicants hereby respectfully request reexamination and reconsideration of the subject application in view of the following amendments and remarks.

An Information Disclosure Statement under 37 C.F.R. §§1.56 and 1.97 is also submitted herewith. Applicants' agent notes that the fee required under 37 C.F.R. § 1.17(p) will also be paid during electronic filing via the Revenue Accounting and Management System.

Furthermore, if it is determined that any additional fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Reply, authorization to charge such fees to Deposit Account No. 02-2955 will be provided during electronic filing.

**Petition for extension of time** begins on page two (2) of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page three (3) of this paper.

**Remarks/Arguments** begin on page eighteen (18) of this paper.

Application No. 10/647,156  
Attorney Docket No. 01-1387  
Response to Office Action dated September 11, 2008

**PETITION FOR EXTENSION OF TIME**

It is hereby petitioned that the period for response be extended by three months pursuant to 37CFR 1.136(a), so that it will expire on March 11, 2009.